Importantly, the on-target in vivo activity of TR-107 was confirmed, as mtDNA copy number was reduced and ClpP substrate proteins such as TFAM, PYCR2, and HMGCS1 were all downregulated in tumor samples from the TR-107-treated group [270]. This evidence concerns the gene CLPP and neoplasm.